Z

Zeiss

Corporate venture capital for deep-tech startups

Business Development Manager - Clinical and Diagnostic

Full-TimeUpdated on 10/23/2026
$116k - $145k/yr+ Sales incentive quota
Senior
Bachelor's, MBA, PhD
Pennsylvania, USA+4 moreMore locations: Virginia, USA | Maryland, USA | Massachusetts, USA | Illinois, USA
RemoteFully remote; best area is the Northeast. Up to 25% global travel.
Growth & MarketingProduct Marketing
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in a relevant field, such as Life Sciences or a related field, is required; an MBA or Ph.D. is a plus.
  • At least 5 years of experience in business development, marketing, or sales in industries related to routine or capital equipment for FDA-regulated or similar spaces related to Clinical and Diagnostic equipment.
  • Proven experience in content development, digital marketing, or managing web platforms.
  • Strong knowledge of the Clinical and Diagnostic market, channel partners, group purchasing organizations and contracts, customer buying journey, and competitive landscape.
  • Ability to integrate and synthesize technical information.
  • Excellent communication, presentation, and negotiation skills.
  • Ability to work independently and in a matrixed global organization.
  • Willingness and ability to travel globally up to 25%.
Responsibilities
  • Drive growth in the number and value of qualified opportunities within the North American Clinical and Diagnostic Customer Segment, measured by subsector and relevant product line.
  • Identify and develop new market opportunities, applications, partnerships, and customer use cases.
  • Deliver timely, high-quality market intelligence, including customer insights, market trends, competitive analysis, and recommended commercial actions.
  • Develop differentiated product positioning, value propositions, and customer-facing content.
  • Engage customers and key opinion leaders, building quality and breadth of relationships across priority subsectors.
  • Build ZEISS solution ecosystems within Clinical and Diagnostic networks and group purchasing organizations.
  • Prepare competitive analysis reports.
  • Manage expenses and assigned budgets in accordance with company guidelines.
  • Develop training and sales enablement initiatives for employees and customers.
  • Improve opportunity-to-order conversion across Clinical Routine, Clinical Diagnostics, and Veterinary Diagnostics subsectors.
  • Monitor and interpret market signals, including customer needs, emerging applications, technology trends, regulatory developments, investment patterns, and competitive activity.
  • Engage prospective and existing customers to understand their jobs to be done, workflows, pain points, decision criteria, purchasing processes, and unmet needs.
  • Maintain an evidence-based understanding of priority markets, customer segments, competitors, substitute technologies, and ZEISS’s relative position.
  • Build relationships with customers, key opinion leaders, industry organizations, channel partners, and group purchasing organizations.
  • Identify unmet market needs and portfolio gaps and communicate prioritized recommendations to regional and global stakeholders.
  • Develop and maintain the North American go-to-market strategy for the Clinical and Diagnostic Customer Segment and related subsectors.
  • Define and prioritize subsectors, customer jobs to be done, applications, buyer personas, target customers, and assigned product lines with the greatest growth potential.
  • Translate market and customer insights into actionable market-development plans with clear objectives, initiatives, timelines, and success measures.
  • Develop opportunities across priority applications and assigned product lines to increase the number, quality, and value of opportunities within the segment.
  • Collaborate with Global Customer Segment counterparts to align strategies while representing North American market requirements.
  • Develop differentiated value propositions, positioning, messaging, and use-case narratives based on customer needs, competitive dynamics, and ZEISS portfolio strengths.
  • Create or serve as subject-matter lead for market-, product-, and application-focused content, including case studies, application notes, articles, customer testimonials, presentations, sales tools, and thought-leadership materials.
  • Collaborate with customers, key opinion leaders, Sales, Applications, and Product Management to develop credible customer stories and market-relevant content.
  • Review materials for technical accuracy, consistent product positioning, and compliance with applicable regulatory and FDA requirements.
  • Provide Marketing Communications with content priorities, target-audience insights, core messaging, and subject-matter expertise; Marketing Communications owns content production, website publishing, campaign execution, distribution, and reach.
  • Equip Sales with customer insights, segment knowledge, competitive guidance, objection-handling tools, value propositions, and relevant content.
  • Lead market-readiness components of new product launches, including market assessment, target-customer definition, positioning, content requirements, and sales training.
  • Provide strategic inputs for targeted campaigns and collaborate with Marketing Communications on campaign activation.
  • Represent ZEISS at selected customer meetings, conferences, trade shows, advisory discussions, and industry events to strengthen relationships, expand market knowledge, and generate opportunities.
  • Facilitate exchange of market intelligence, customer feedback, competitive insights, and commercial success stories across North American and global teams.
  • Monitor qualified opportunity development by segment, subsector, product line, source, and strategic initiative.
  • Evaluate the contribution of customer engagement, content, sales enablement, product launches, partnerships, and other market-development activities to commercial outcomes.
  • Partner with Marketing Communications to interpret campaign, content, website, audience, and channel-performance data.
  • Use performance data, customer feedback, and sales insights to refine market priorities, positioning, content, and go-to-market plans.
  • Provide regular business updates summarizing market developments, progress against objectives, commercial impact, lessons learned, and recommended actions.
Desired Qualifications
  • An MBA or Ph.D. is a plus.

About the company

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$67.7M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-half 2025/26 revenue reached €5.841 billion, with EBIT rising to €955 million.
  • ZEISS CLINIC 360 won FDA 510(k) clearance on August 19, 2026.
  • EURETINA 2026 launches expanded retina imaging, cataract systems, and DORC brand integration.

What critics are saying

  • ZEISS Meditec plans up to 1,000 cuts by 2029, signaling margin pressure.
  • Göttingen workers entered mediation in February 2026 after Zeiss targeted roughly 140 jobs.
  • ASML scanner timing controls ZEISS SMT revenue; any slip delays optics demand immediately.

What makes Zeiss unique

  • ZEISS supplies ASML's exclusive EUV optics, anchoring High-NA lithography through 2030.
  • ZEISS Medical Technology bundles imaging, software, and surgery across one ophthalmic workflow stack.
  • ZEISS CLINIC 360 and Collaborative Care tie devices, cloud analytics, and referrals together.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Performance Bonus

Company News

Associated Press
Oct 12th, 2026
ZEISS launches NLX X-ray inspection and DUNE wafer warpage correction for advanced chip packaging

ZEISS Semiconductor Manufacturing Technology (SMT) has launched two systems for advanced chip packaging: ZEISS NLX and ZEISS DUNE. The company announced them in San Francisco on October 12, 2026, as chips grow more complex. ZEISS NLX inspects the inside of chip packages without damaging them. It helps manufacturers spot defects in connections between stacked dies early, and it handles 300-millimetre wafers in both process development and high-volume production. ZEISS DUNE measures the topography of a wafer and corrects wafer bow individually. This helps avoid yield losses in downstream processing and prepares bonding processes. ZEISS SMT is showing the systems at SEMICON West, alongside its photomask tools. The company is also marking 100 years of business in the US in 2026.

PR Newswire
Sep 24th, 2026
ZEISS unveils retinal imaging and surgical innovations at EURETINA 2026

ZEISS Medical Technology has announced expansions to its ZEISS Retina Workflow at the EURETINA 2026 congress in Vienna. The company introduced the ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device for streamlined retinal diagnostics. ZEISS also unveiled the HMDmd CR3, a head-mounted 3D display that connects with the ZEISS ARTEVO 850 surgical microscope. The company reported that its DORC ILM-BLUE and DORC MEMBRANEBLUE-DUAL vitreoretinal surgical dyes reached a 3 million milestone. Additionally, ZEISS announced that the DORC brand will be consolidated under the ZEISS brand name, unifying the company's ophthalmic offerings. The DORC TDC VELOCE cutter continues to show improvements in 27G vitrectomy procedures, with clinical data suggesting up to 41% shorter core vitrectomy times.

PR Newswire
Sep 17th, 2026
ZEISS expands retinal imaging portfolio with new ALTA DUO 300 multimodal OCT device

ZEISS Medical Technology has expanded its retinal imaging portfolio with the launch of ZEISS ALTA DUO 300, a fully automated, compact multimodal imaging solution. The device combines optical coherence tomography (OCT) and fundus photography in a single unit, designed to provide efficient retinal assessment for eye care practices. The ALTA DUO 300 features four key diagnostic technologies: automated structural OCT with reference database and reporting, true colour fundus camera, AI-enhanced OCT-Angiography, and full chamber depth anterior OCT scanning. The device aims to integrate retinal imaging into everyday patient care through simplified workflows. The product will be showcased at the European Society of Retina Specialists congress in Vienna from 1-4 October and will be available in select markets later in 2026.

Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.